Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
To the Editor: Dr Als-Nielsen and colleagues1 stated that "[i]n principle, about half of all
trials should favor the control intervention." The authors' findings reflect
that expectation that "The experimental drug was recommended as treatment
of choice in . . . 51% of trials funded by for-profit organizations." The
authors do not explain, however, why the trials performed by nonprofit organizations
had a lower percentage.
Rosefsky JB. Results of Clinical Trials Sponsored by For-Profit vs Nonprofit EntitiesResults of Clinical Trials Sponsored by For-Profit vs Nonprofit Entities. JAMA. 2003;290(23):3070. doi:10.1001/jama.290.23.3070-a